Gonghua Qi

552 total citations
16 papers, 365 citations indexed

About

Gonghua Qi is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Gonghua Qi has authored 16 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in Gonghua Qi's work include PARP inhibition in cancer therapy (5 papers), DNA Repair Mechanisms (4 papers) and Autophagy in Disease and Therapy (3 papers). Gonghua Qi is often cited by papers focused on PARP inhibition in cancer therapy (5 papers), DNA Repair Mechanisms (4 papers) and Autophagy in Disease and Therapy (3 papers). Gonghua Qi collaborates with scholars based in China and United States. Gonghua Qi's co-authors include Hanlin Ma, Beihua Kong, Jiali Peng, Xingsheng Yang, Margaux J. Kanis, Cunzhong Yuan, Beihua Kong, Fang Han, Yingwei Li and Minghao Li and has published in prestigious journals such as Cell Reports, Journal of Cellular Physiology and Cell Death and Disease.

In The Last Decade

Gonghua Qi

15 papers receiving 361 citations

Peers

Gonghua Qi

ONCOL

Boer Shan China

Christopher McCann United Kingdom

Ting‐Tai Yen United States

Shujie Pang China

Koji Nishino Japan

Gonzalo Giornelli Argentina

Imre Pete Hungary

ME Sherman United States

JH Kim South Korea

Miłosz Wilczyński Poland

Boer Shan China

Gonghua Qi

81 ×0.5

145 ×1.4

105 ×1.0

ONCOL

149 ×1.6

84 ×1.2

Citations per year, relative to Gonghua Qi Gonghua Qi (= 1×) peers Boer Shan

Countries citing papers authored by Gonghua Qi

Since Specialization

Citations

This map shows the geographic impact of Gonghua Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gonghua Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gonghua Qi more than expected).

Fields of papers citing papers by Gonghua Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gonghua Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gonghua Qi. The network helps show where Gonghua Qi may publish in the future.

Co-authorship network of co-authors of Gonghua Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Gonghua Qi. A scholar is included among the top collaborators of Gonghua Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gonghua Qi. Gonghua Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Qi, Gonghua, et al.. (2025). Insufficient expression of COL6A1 promotes the development of early-onset severe preeclampsia by inhibiting the APJ/AKT signaling pathway. Cell Death Discovery. 11(1). 81–81. 2 indexed citations

Han, Fang, Gonghua Qi, Rongrong Li, et al.. (2025). USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer. Cell Death and Disease. 16(1). 305–305. 3 indexed citations

Teng, Kai, Hanlin Ma, Panpan Gai, Xuelian Zhao, & Gonghua Qi. (2025). SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway. Cell Death Discovery. 11(1). 29–29. 7 indexed citations

Qi, Gonghua, et al.. (2025). TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer. Communications Biology. 8(1). 1011–1011.

Qi, Gonghua, Hanlin Ma, Kai Teng, et al.. (2024). SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway. APOPTOSIS. 30(1-2). 83–98. 3 indexed citations

Ma, Xinyue, Chenggong Sun, Chen Zhao, et al.. (2023). Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis. Cell Reports. 42(8). 112944–112944. 15 indexed citations

Ma, Hanlin, et al.. (2023). HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway. Cell Communication and Signaling. 21(1). 144–144. 17 indexed citations

Bu, Hualei, Zhaoyang Zhang, Ran Chu, et al.. (2023). Clinical features and prognostic factors analysis of intravenous leiomyomatosis. Frontiers in Surgery. 9. 1020004–1020004. 8 indexed citations

Ma, Hanlin, Gonghua Qi, Fang Han, et al.. (2022). HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer. Cell Death and Disease. 13(3). 263–263. 31 indexed citations

10.

Ma, Hanlin, Gonghua Qi, Fang Han, et al.. (2022). PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer. Experimental & Molecular Medicine. 54(7). 999–1010. 20 indexed citations

11.

Qi, Gonghua, et al.. (2021). TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway. Cell Death and Disease. 12(12). 1135–1135. 36 indexed citations

12.

Qi, Gonghua, Chenyi Zhang, Hanlin Ma, et al.. (2021). CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer.. PubMed. 11(2). 389–415. 30 indexed citations

13.

Ma, Hanlin, Fang Han, Xiaohui Yan, et al.. (2020). PBK promotes aggressive phenotypes of cervical cancer through ERK/c‐Myc signaling pathway. Journal of Cellular Physiology. 236(4). 2767–2781. 27 indexed citations

14.

Ma, Hanlin, Yingwei Li, Xiangxiang Wang, et al.. (2019). PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma. Cell Death and Disease. 10(3). 166–166. 55 indexed citations

15.

Zhang, Qing, Wenhui Li, Margaux J. Kanis, et al.. (2017). Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis. Oncotarget. 8(28). 46580–46592. 64 indexed citations

16.

Zhang, Qing, Gonghua Qi, Margaux J. Kanis, et al.. (2017). Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget. 8(34). 57642–57653. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact